CoChat
Sign Up
Cited by 50Aldose Reductase and TaurineBlood Pressure and Hypertension StudiesBiochemical effects in animals

The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis

Open access
Waldron, Mark, Patterson, Stephen David, Tallent, Jamie, Jeffries, Owen·2018·Current Hypertension Reports
DOI 10.1007/s11906-018-0881-z
Open this paper in CoChat — free account

Abstract

Purpose of review The aims of this meta-analysis were to investigate the effects of orally administered isolated taurine on resting systolic blood pressure (SBP) and diastolic blood pressure (DBP) in humans. Recent findings There is growing evidence that taurine deficiency is associated with hypertension and that oral supplementation can have antihypertensive effects in humans. However, these investigations have been conducted across a number of decades and populations and have not been collectively reviewed. A search was performed using various databases in May 2018 and later screened using search criteria for eligibility. There were seven peer-reviewed studies meeting the inclusion criteria, encompassing 103 participants of varying age and health statuses. Taurine ingestion reduced SBP (Hedges' g = - 0.70, 95% CI - 0.98 to - 0.41, P < 0.0001) and DBP (Hedges' g = - 0.62, 95% CI - 0.91 to - 0.34, P < 0.0001). These results translated to mean ~ 3 mmHg reductions in both SBP (range = 0-15 mmHg) and DBP (range = 0-7 mmHg) following a range of doses (1 to 6 g/day) and supplementation periods (1 day to 12 weeks), with no adverse events reported. These preliminary findings suggest that ingestion of taurine at the stated doses and supplementation periods can reduce blood pressure to a clinically relevant magnitude, without any adverse side effects. Future studies are needed to establish the effects of oral taurine supplementation on targeted pathologies and the optimal supplementation doses and periods.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11906-018-0881-z

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dietary supplementation of nitrate through beet juice induces an increase in plasma nitrite concentration, subsequently increasing nitric oxide production.

    “Dietary supplementation of nitrate (NO3 -) through beet juice induces an increase in the concentration of nitrite (NO 2) in plasma [40] subsequently increasing the production of nitric oxide (NO) [41].”

    From Dietary and Ergogenic Supplementation to Improve Elite Soccer Players’ Performance (2021) · cites this paper as [40]

    The Discussion (p. 7) mentions beetroot juice only as a comparison for blood-pressure effects, and the References (p. 13) list a review of nitrate and beetroot juice supplementation. Searches for plasma nitrite and nitric oxide production found no passage addressing the claimed mechanism. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 48

  1. [2]2. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-60.
  2. [3]3. Smith SC, Benjamin EJ, Bonow RO, et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. Circulation 2011, 124:2458-73.
  3. [4]4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC VII report. JAMA 2003, 289:2560-2572.
  4. [5]5. Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995, 155:701-9.
  5. [6]6. Appel LJ, Brands MW, Daniels SR, et al., Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006, 47:296-308.
  6. [7]7. COLLABORATION BPLTT: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362: 1527-1535.
  7. [8]8. Savica V, Bellinghieri G, Kopple JD. The effect of nutrition on blood pressure. Annu Rev Nutr 2010, 30:365-401.
  8. [9]9. Xu Y, Arneja AS, Tappia PS, et al. The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol 2008, 13:57-65.
  9. [10]10. Schaffer SW, Ito T, Azuma J. Clinical significance of taurine. Amino Acids 2014, 46:1-5.
  10. [11]11. Laidlaw SA, Grosvenor M, Kopple JD. The taurine content of common foodstuffs. Parenter Enteral Nutr 1990, 14:183-8.
  11. [12]12. Huxtable JR. Physiological actions of taurine. Physiol Rev 1992, 72:101-63.
  12. [13]13. Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol 1998, 30:451-463.
  13. [14]14. Liao XB, Zhou XM, Li JM, et al. Taurine transporter is expressed in vascular smooth muscle cells. Amino Acids 2007, 33:639-43.
  14. [15]15. Ulusoy KG, Kaya E, Karabacak K et al. Taurine relaxes human radial artery through potassium channel opening action. Korean J Physiol Pharmacol 2017, 21:617-623.
  15. [16]16. Yoshioka M, Takasugi Y, Koga Y. Central hypotensive effect involving neurotransmitters of long-term administration of taurine to stroke-prone spontaneously hypertensive rat. Masui 2007, 56:139-47.
  16. [17]17. Ito T, Schaffer S, Azuma J. The effect of taurine on chronic heart failure: actions of taurine against catecholamine and angiotensin II. Amino Acids 2014, 46:111-9.
  17. [18]18. ** Sagara M, Murakami S, Mizushima S. et al. Taurine in 24-h urine samples is inversely related to cardiovascular risks of middle aged subjects in 50 populations of the world. Adv Exp Med Biol 2015, 803:623-36. This multi-centre, cross-sectional study of &gt; 4,000 patients demonstrated an inverse relationship between 24-h urinary taurine/creatinine ratios and both hypertension and obesity, highlighting the links between taurine deficiency and cardiovascular disease risk.
  18. [20]20. Higgins JP, Altman DG. Assessing Risk of Bias in Included Studies, in Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series (eds JP Higgins, S Green) Chichester: John Wiley &amp; Sons Ltd; 2008.
  19. [22]22. Rosenthal R, Rosnow RL. Essentials of Behavioral research: methods and data analysis. New York: McGraw-Hill; 1984.
  20. [23]23. Satoh H, Kang J. Modulation by taurine of human arterial stiffness and wave reflection. Adv Exp Med Biol 2009, 643:47-55.
  21. [24]24. Mizushima S, Nara Y, Sawamura M. et al. Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Adv Exp Med Biol 1996, 403:615-22.
  22. [25]25. Ahmadian M, Roshan VD, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. J Diet Supp 2017, 14:422-32.
  23. [26]26. Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol 2011, 57:333-7.
  24. [27]27. Fujita T, Ando K, Noda H, et al.Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 1987, 75:525-32.
  25. [28]28. Warnock R, Jeffries O, Patterson S, Waldron M. The effects of caffeine, taurine or caffeine-taurine coingestion on repeat-sprint cycling performance and physiological responses. Int J Sports Physiol Perform 2017, 24:1-24.
  26. [29]29. Schwarzer R, Kivaranovic D, Mandorfer M. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther 2018, 47:86-94.
  27. [31]31. Moloney MA, Casey RG, O'Donnell DH. et al. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc Dis Res 2010, 7:300-10.
  28. [32]32. Siervo M, Lara J, Ogbonmwan I. et al. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr 2013, 143:818-26.
  29. [34]34. Liang W, Ma H, Cao L, Yan W. et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis . J Cell Mol Med 2017, 21:2634-2642.
  30. [35]35. Peck RN, Smart LR, Beier R et al. Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. BMC Nephrol 2013, 14:201.
  31. [36]36. Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and Larginine. Regul Toxicol Pharmacal 2008, 50:376-399.
  32. [37]37. Ristori MT, Verdetti J. Effects of taurine on rat aorta in vitro . Fundam Clin Pharmacol 1991, 5:245-258.
  33. [38]38. Niu LG, Zhang MS, Liu Y. et al. Vasorelaxant effect of taurine is diminished by tetraethylammonium in rat isolated arteries. Eur J Pharmacol 2008, 580:169-174.
  34. [39]39. Nishida S, Satoh H. Vascular modulation of rat aorta by taurine. Adv Exp Med Biol 2009, 643:37-46.
  35. [40]40. Liu Y, Niu L, Zhang W. et al. Effect of taurine on contractions of the porcine coronary artery. Pharmacol Rep 2009, 61:681-689.
  36. [41]41. Fanconi F, Giotti A, Manzini S. et al. The effect of taurine on High potassium- and noradrenaline-induced contraction in rabbit ear artery. Br J Pharmacol 1982, 75:605-612.
  37. [42]42. Fujita T, Sato Y. The antihypertensive effect of taurine in DOCA-salt rats. J Hypertens Suppl 1984, 2:S5635.
  38. [43]43. Hano T, Kasano M, Tomari H. et al.Taurine suppresses pressor response through the inhibition of sympathetic nerve activity and the improvement in baro-reflex sensitivity of spontaneously hypertensive rats. Adv Exp Med Biol 2009, 643:57-63.
  39. [44]44. Tian XY, Wong WT, Sayed N. et al. NaHS relaxes rat cerebral artery in vitro via inhibition of l-type voltage-sensitive Ca2+ channel. Pharmacol Res 2012, 65:239-246.
  40. [45]45. Li C, Cao L, Zeng Q, et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type 2 receptor expression. Cardiovasc Drugs Ther 2005, 19:105-12.
  41. [46]46. Jeevanandam M, Young DH, Ramias L. et al. Effect of major trauma on plasma free amino acid concentrations in geriatric patients. Am J Clin Nutr 1990, 51:1040-1045.
  42. [47]47. Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. Curr Opin Clin Nutr Metab Care 2000, 3:417-24.
  43. [48]48. Franconi F, Bennardini F, Mattana A. et al. Plasma and platelet taurine are reduced in subjects with insulindependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 1995, 61:1115-1119.
  44. [49]49. Henriksson J. Effect of exercise on amino acid concentrations in skeletal muscle and plasma. J Exp Biol 1991, 160:149-165.
  45. [51]51. Waldron M, Patterson SD, Tallent J, Jeffries O. The Effects of an Oral Taurine Dose and Supplementation Period on Endurance Exercise Performance in Humans: A Meta-Analysis. Sports Med 2018, 48:1247-1253.
  46. [52]52. Waldron M, Knight F, Tallent J, Patterson S, Jeffries O. The effects of taurine on repeat sprint cycling after low or high cadence exhaustive exercise in females. Amino Acids 2018, 50:663-669.
  47. [53]53. Baum M, Weiss M. The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. Amino Acids 2001, 20:75-82.
  48. [54]54. Galloway SD, Talanian JL, Shoveller AK. et al. Seven days of oral taurine supplementation does not increase muscle taurine content or alter substrate metabolism during prolonged exercise in humans. J Appl Physiol 2008, 105:643-651.

Cited by

Sorted by citations

Authors
Waldron, M., Patterson, S. D., Tallent, J., & Jeffries, O.
Affiliations
St Mary's University Twickenham London (GB)
Corresponding author
Waldron, Mark
ORCID
Venue
Current Hypertension Reports
Publisher
Springer Science and Business Media LLC
Published
2018-07-13
Volume
20
Issue
9
Pages
81-81
ISSN
  • 1522-6417 (ISSN-L)
  • 1534-3111
DOI
10.1007/s11906-018-0881-z
OpenAlex
W2884902042
Cited by
50
References
3
Citations by year
2026: 3 · 2025: 6 · 2024: 7 · 2023: 10 · 2022: 6 · 2021: 4 · 2020: 9 · 2019: 5
FWCI
0.51
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Hypertension Reports (publishedVersion)
  • PubMed (publishedVersion)
  • St Mary's University Repository (ULCC) (acceptedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Physiology › Biochemical effects in animals
Keywords
taurine, oral supplementation, blood pressure, systolic blood pressure, diastolic blood pressure, hypertension, antihypertensive effect, taurine deficiency
MeSH terms
Blood Pressure, Diastole, Humans, Systole, Taurine, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review